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Mutations in the LRRK2 gene cause autosomal dominant Parkinson’s disease. LRRK2 encodes a multi-
domain protein containing a Ras-of-complex (Roc) GTPase domain, a C-terminal of Roc domain and a protein
kinase domain. LRRK2 can function as a GTPase and protein kinase, although the interplay between these
two enzymatic domains is poorly understood. Although guanine nucleotide binding is critically required
for the kinase activity of LRRK2, the contribution of GTP hydrolysis is not known. In general, the molecular
determinants regulating GTPase activity and how the GTPase domain contributes to the properties of LRRK2
remain to be clarified. Here, we identify a number of synthetic missense mutations in the GTPase domain that
functionally modulate GTP binding and GTP hydrolysis and we employ these mutants to comprehensively
explore the contribution of GTPase activity to the kinase activity and cellular phenotypes of LRRK2. Our
data demonstrate that guanine nucleotide binding and, to a lesser extent, GTP hydrolysis are required for
maintaining normal kinase activity and both activities contribute to the GTP-dependent activation
of LRRK2 kinase activity. Guanine nucleotide binding but not GTP hydrolysis regulates the dimerization,
structure and stability of LRRK2. Furthermore, GTP hydrolysis regulates the LRRK2-dependent inhibition
of neurite outgrowth in primary cortical neurons but is unable to robustly modulate the effects of the familial
G2019S mutation. Our study elucidates the role of GTPase activity in regulating kinase activity and cellular
phenotypes of LRRK2 and has important implications for the validation of the GTPase domain as a molecular
target for attenuating LRRK2-mediated neurodegeneration.
INTRODUCTION
Mutations in the leucine-rich repeat kinase 2 (LRRK2) gene
are a common cause of late-onset, autosomal dominant famil-
ial Parkinson’s disease (PD) (1–3). The LRRK2 gene encodes
a 2527 amino acid multi-domain protein containing a central
catalytic region consisting of a Ras-of-complex (Roc)
GTPase domain and a serine/threonine-directed protein
kinase domain connected by a C-terminal of Roc (COR)
domain (4). The Roc-COR tandem region of LRRK2 is char-
acteristic of members of the ROCO protein family that in
humans consists of four members, LRRK1, LRRK2,
DAPK1 and MFHAS1 (5,6). LRRK2 also contains several
regions implicated in protein–protein interactions including
armadillo, ankyrin, leucine-rich and WD40 repeat domains.
Similar to other small GTPases, the GTPase domain of
LRRK2 binds guanine nucleotides via a phosphate-binding
motif (P-loop) region (residues 1341–1348, GNTGSGKT)
and can hydrolyze GTP, although at a slow rate, involving a
catalytic Switch II motif (residues 1394–1398, DFAGR)
(7–11). The Switch II motif of LRRK2 contains an Arg (R)
residue at position 1398, whereas a similarly charged Gln
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(Q) residue occupies the equivalent position in the majority of
small GTPases and is critical for GTPase activity. In the
related ROCO proteins LRRK1 and MFHAS1, the equivalent
R1398 residue is substituted to Pro (DIGGP) or Asp
(DLAGD), respectively (5,6), thereby suggesting a distinct
mechanism of regulation of ROCO proteins compared with
other small GTPase family members. Although a QL sub-
stitution in Ras GTPases results in a GTPase-inactive protein
that is ‘GTP-locked’ and constitutively active, the equivalent
R1398L substitution in LRRK2 oppositely enhances its
GTPase activity (12,13). The identification of an equivalent
‘GTP-locked’ mutation in LRRK2 has so far proved elusive
but will prove valuable for determining the structure and ac-
tivity of LRRK2 in a presumably GTP-bound conformation.
In general, the molecular determinants regulating the
GTPase activity of LRRK2 remain poorly defined and how
the GTPase domain functionally interacts with the kinase
domain is incompletely understood. PD-related mutations in
LRRK2 either lead to enhanced kinase activity (i.e.
G2019S) or to reduced GTPase activity (i.e. R1441C,
R1441G or Y1699C), suggesting that both kinase and
GTPase activities are important for the development of PD
due to LRRK2 mutations (8,9,13–16). Furthermore, pathogen-
ic mutations in LRRK2 promote neuronal toxicity through a
guanine nucleotide-binding and kinase-dependent mechanism
(10,11,16). Therefore, the GTPase domain represents a poten-
tially promising molecular target for modulating LRRK2 ac-
tivity and neuronal toxicity.
Small GTPases normally act as molecular switches that
cycle between GTP-bound ‘active’ and GDP-bound ‘inactive’
states, with the GTP-bound state leading to the binding and
activation of downstream effector proteins such as kinases,
i.e. the activation of Raf kinase by Ras GTPase. For
LRRK2, an intact GTPase domain is critically required for
kinase activity since the disruption of guanine nucleotide
binding by the introduction of P-loop null mutations (i.e.
K1347A or T1348N) results in a kinase-inactive form of
LRRK2 (10,11). Although guanine nucleotide binding
appears to be critically required for the kinase activity of
LRRK2, the relative contributions of GDP and GTP binding
are unclear. The kinase activity of LRRK2 is enhanced
by treatment of cell lysates with GTP or its analogs prior
to LRRK2 purification, whereas the direct binding of GTP
to purified LRRK2 in vitro fails to similarly enhance its
kinase activity (11,17). These observations suggest that
LRRK2 kinase activity can be influenced by the ability for
GTP binding rather than by direct GTP binding and imply
that an unidentified guanine nucleotide-binding protein
could be required for the GTP-dependent kinase activation
of LRRK2 that occurs in cells. Therefore, the relationship
between the GTPase and kinase domains of LRRK2 does
not initially appear to conform to a classical activation mech-
anism similar to the Ras-Raf pathway. At present, we under-
stand little about the overall contribution of the GTPase
domain to the enzymatic, biochemical and cellular properties
of LRRK2. Accordingly, in the present study, we develop a
collection of functional GTPase domain mutants that modu-
late GTP binding and hydrolysis to comprehensively explore
the contribution of GTPase activity to the biochemical and
cellular phenotypes of LRRK2.
RESULTS
Development of LRRK2 GTPase and kinase domain
functional mutants
To begin to explore the contribution of the GTPase domain to the
properties of LRRK2, we developed a panel of full-length FLAG-
tagged human LRRK2 expression constructs containing a collec-
tion of synthetic mutations analogous to well-characterized func-
tional residues in members of the Ras GTPase superfamily
(Table 1). We introduced missense mutations in the P-loop
motif that disrupt guanine nucleotide binding (K1347A,
T1348N and G2019S/T1348N) (11), in the Switch II motif that
are predicted to modulate GTP hydrolysis (R1398L, R1398L/
T1343V and R1398Q/T1343G) (7,12,13), in the kinase domain
that impair (K1906M, D1994A, D1994N, G2019S/K1906M,
G2019S/D1994A and G2019S/D1994N) or enhance (G2019S)
kinase activity (10,11,14,16), and various combinations of muta-
tions of the GTPase domain together with kinase-inactive
(D1994A/R1398L and D1994A/R1398L/T1343V) or
kinase-enhanced (G2019S/R1398L and G2019S/R1398L/
T1343V) variants (Fig. 1 and Table 1). We first analyzed the
effects of each mutation on the steady-state levels of LRRK2
protein transiently expressed in HEK-293T cells. The majority
of mutations produce similar steady-state levels of LRRK2
protein compared with wild-type (WT) LRRK2, although the
P-loop mutations, K1347A and T1348N, cause a significant re-
duction of LRRK2 levels (Fig. 2A and B). Our data reveal that
mutations in functional residues of the GTPase and kinase
domains are generally well-tolerated and do not have major
effects on the steady-state levels of LRRK2 protein, with the
notable exception of P-loop mutations that are known to disrupt
guanine nucleotide binding (11).
Identification of mutations that modulate LRRK2 GTP
binding and GTP hydrolysis
We next sought to confirm the functional effects of these
mutations on LRRK2 GTPase activity by conducting well-
established assays to measure GTP binding and GTP hydroly-
sis (11–13). For assessments of GTP binding, pull-down
assays were conducted with GTP-agarose on cell extracts
expressing each LRRK2 variant to determine the relative
level of GTP binding (Table 1). Compared with WT
LRRK2, the K1347A, T1348N and G2019S/T1348N muta-
tions which disrupt the guanine nucleotide-binding P-loop
motif significantly impair the GTP binding of LRRK2
(Fig. 3A), as previously reported (11). Unexpectedly, the
kinase-inactive forms of Switch II motif variants (D1994A/
R1398L and D1994A/R1398L/T1343V) impair GTP binding
to a degree similar to P-loop mutations (Fig. 3A). Kinase ac-
tivity is not required for the normal GTP binding of LRRK2
as suggested by the normal GTP binding of kinase-inactive
(i.e. K1906M, D1994A and D1994N) or kinase-enhanced
(i.e. G2019S) mutants (Fig. 3A). These data demonstrate
that an intact P-loop motif is critically required for normal
GTP binding of LRRK2.
We next explored the effects of GTPase and kinase domain
mutations on LRRK2-mediated GTP hydrolysis by measuring
the release of free g-phosphate from GTP (12,13). We first estab-
lished time–response curves, using three known LRRK2 variants
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that are GTPase-active (WT), GTPase-impaired (T1348N) or
GTPase-enhanced (R1398L). As predicted, WT and, to a
greater extent, R1398L variants produce a marked time-
dependent increase in GTP hydrolysis compared with the
T1348N variant over a period of 120 min (Fig. 3B). The residual
hydrolysis mediated by the T1348N mutant in this assay may
reflect low-level GTPase activity of this mutant, consistent with
reduced but not completely impaired GTP binding. For subse-
quent assays, we monitored GTP hydrolysis over 120 min for
comparisons among LRRK2 mutations (Table 1). We find that
P-loop mutations (K1347A, T1348N and G2019S/T1348N)
markedly impair LRRK2 GTP hydrolysis compared with WT
protein (Fig. 2C), consistent with their impaired GTP binding
(Fig. 3A). Mutations that alter kinase activity (K1906M,
D1994A, D1994N and G2019S) do not significantly influence
GTPase activity (Fig. 3C). The R1398L and G2019S/R1398L
mutations consistently and significantly enhance GTP hydrolysis
(Fig. 3C). We have previously reported that the introduction of
Ras-like R1398Q/T1343G mutations into a Roc-COR-kinase
domain fragment of LRRK2 (residues 1300–2163) modestly
enhances GTP hydrolysis (13); however, in the context of full-
length LRRK2, these mutations no longer have a significant
effect (Fig. 3C). Importantly, the R1398L/T1343V mutant, analo-
gous to a GTP-locked version of Ras, markedly impairs LRRK2
GTPase activity despite displaying normal GTP binding (Fig. 3A
and C). The R1398L/T1343V mutant therefore represents a
GTPase-inactive, presumably GTP-locked form of LRRK2.
Interestingly, the introduction of the G2019S mutation to the
R1398L/T1343V variant (G2019S/R1398L/T1343V) restores
normal GTPase activity, suggesting that the effects of the
R1398L/T1343V variant on GTPase activity are kinase-
dependent (Fig. 3C). Notably, the introduction of the
kinase-inactive D1994A mutation has no effect on the diminished
GTPase activity of the R1398L/T1343V variant (Fig. 3C). Col-
lectively, we have identified functional mutations within the cata-
lytic Switch II motif that robustly enhance (R1398L) or impair
(R1398L/T1343V) the GTPase activity of LRRK2 independent
of GTP binding (Table 1). Our data also confirm that P-loop muta-
tions (i.e. K1347A and T1348N) impair the GTP binding and
GTP hydrolysis of LRRK2.
Table 1. LRRK2 GTPase and kinase domain mutations and expected/observed functional effects
Mutation Domain/motif Expected effect (relative to WT
LRRK2)
GTP binding
(observed)
GTP hydrolysis
(observed)
Kinase activity
(observed)
T1343G GTPase/P-loop ? – – –
K1347A GTPase/P-loop Impaired guanine nucleotide
binding
  
T1348N GTPase/P-loop Impaired guanine nucleotide
binding
  
R1398L GTPase/Switch II Impaired GTP hydrolysis –  –/
R1398Q GTPase/Switch II Ras-like; enhanced GTP
hydrolysis
– – –
K1906M Kinase/ATP-binding site Kinase-inactive – – 
D1994A Kinase/proton-acceptor
site
Kinase-inactive – – 
D1994N Kinase/proton-acceptor
site
Kinase-inactive – – 
G2019S Kinase/activation loop Enhanced kinase activity – – 
R1398L/T1343V GTPase/P-loop and
Switch II
Impaired GTP hydrolysis –  
R1398Q/T1343G GTPase/P-loop and
Switch II
Ras-like; enhanced GTP
hydrolysis
– – –
D1994A/R1398L Kinase and GTPase ?   
G2019S/T1348N Kinase and GTPase Kinase-inactive   
G2019S/R1398L Kinase and GTPase ? –  
G2019S/K1906M Kinase Kinase-inactive – – 
G2019S/D1994A Kinase Kinase-inactive – – 
G2019S/D1994N Kinase Kinase-inactive – – 
D1994A/R1398L/
T1343V
Kinase and GTPase ?   
G2019S/R1398L/
T1343V
Kinase and GTPase ? – – /
The shading divides functional classes of mutations i.e. GTPase versus kinase, but also single, double and triple mutations.
Figure 1. Domain architecture of LRRK2 and the locations of functional
GTPase and kinase domain mutations used in this study. Indicated are func-
tional missense mutations within the guanine nucleotide-binding P-loop
motif and Switch II catalytic motif within the Roc GTPase domain, and the
ATP-binding site, proton-acceptor site and the activation loop of the kinase
domain.
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GTP binding and GTP hydrolysis are required for LRRK2
kinase activity
Having identified GTPase domain mutations that significantly
modulate GTPase activity, we next explored the effects of
altering GTPase activity on the kinase activity of LRRK2.
We first measured LRRK2 autophosphorylation by conducting
in vitro radioactive kinase assays with immunopurified,
soluble full-length LRRK2 variants and [33P]-g-ATP. As
expected, kinase-inactive LRRK2 variants (D1994A and
D1994N) dramatically impair, whereas the pathogenic
G2019S mutation enhances autophosphorylation activity of
LRRK2 compared with the WT protein (Fig. 4A and B).
The G2019S/D1994A and G2019S/D1994N variants prevent
the G2019S-mediated increase in LRRK2 autophosphoryla-
tion, as predicted, since the D1994 site serves as a key catalyt-
ic residue of the kinase domain, i.e. the proton acceptor
(Fig. 4A and B). P-loop mutants (K1347A, T1348N and
G2019S/T1348N) also markedly impair LRRK2 autopho-
sphorylation (Fig. 4A and B), as previously reported
(7,10,11), confirming that guanine nucleotide-binding capacity
is critically required for kinase activity. The Ras-like mutant,
R1398Q/T1343G, fails to influence kinase activity (Fig. 4A
and B), consistent with its normal GTP-binding and GTP hy-
drolysis activities (Fig. 3). Unexpectedly, the R1398L and
R1398L/T1343V mutants, which oppositely enhance or
impair GTPase activity, respectively (Fig. 3C), significantly
reduce the autophosphorylation activity of LRRK2 (Fig. 4A
and B) but to a smaller extent than P-loop mutations.
However, combining the R1398L and R1398L/T1343V muta-
tions with the G2019S mutation (G2019S/R1398L and
G2019S/R1398L/T1343V) does not alter the enhanced
LRRK2 autophosphorylation induced by the G2019S mutation
(Fig. 4A and B), suggesting that the G2019S variant super-
sedes the modest effects of these GTPase variants on kinase
activity. It should be noted, however, that the G2019S/
R1398L/T1343V variant displays normal GTP-binding and
hydrolysis activities (Fig. 3), consistent with its lack of
effect on the elevated autophosphorylation activity of
G2019S LRRK2.
The effects of GTPase and kinase domain mutations were
also compared by assessing LRRK2-mediated phosphorylation
of LRRKtide, a well-characterized pseudosubstrate peptide of
LRRK2 (14). We obtained largely similar results compared
with LRRK2 autophosphorylation assays with single or
double mutants containing kinase-inactive (K1906M,
D1994A, D1994N, G2019S/K1906M, G2019S/D1994A,
G2019S/D1994N, D1994A/R1398L and D1994A/R1398L/
T1343V) or guanine nucleotide-binding-deficient mutations
(K1347A, T1348N and G2019S/T1348N) leading to a dramat-
ic impairment of kinase activity compared with WT LRRK2,
whereas the G2019S mutation robustly enhances kinase activ-
ity (Fig. 4C). The Ras-like R1398Q/T1343G variant fails to
alter LRRK2 kinase activity. Consistent with our autopho-
sphorylation data, the R1398L/T1343V variant significantly
reduces LRRK2 kinase activity by 60% but to a lesser
Figure 2. Steady-state protein levels of LRRK2 GTPase domain mutants in HEK-293T cells. (A) Western blot analysis of Triton-soluble fractions derived from
HEK-293T cells transiently expressing FLAG-tagged human LRRK2 (WT or functional mutants) with anti-FLAG antibody to determine the steady-state levels
of LRRK2 or anti-b-tubulin as protein-loading control. Molecular weight markers are indicated in kilodaltons. (B) Densitometric analysis of LRRK2 levels
normalized to b-tubulin expressed in arbitrary units. Bars represent mean+SEM (n ¼ 5–6 experiments). ∗P , 0.05 compared with WT LRRK2 by
one-way ANOVA with the Newman–Keuls post hoc analysis.
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extent than P-loop mutations (Fig. 4C). However, the R1398L
mutation fails to significantly alter LRRK2 kinase activity
(Fig. 4C). The R1398L and R1398L/T1343V variants fail to
significantly attenuate the kinase-enhancing effects of the
G2019S mutation (Fig. 4C). Taken together, our data
suggest that modulating GTPase activity via the R1398L and
R1398L/T1343V mutations modestly attenuates kinase activ-
ity, suggesting that normal GTPase activity is required in
part for the kinase activity of LRRK2. However, modulating
GTPase activity is not sufficient to reduce the enhanced
kinase activity induced by the pathogenic G2019S mutation.
Moreover, guanine nucleotide-binding capacity (i.e. K1347A
or T1348N) is critically required for normal LRRK2 kinase ac-
tivity and for the kinase-enhancing effects of the G2019S mu-
tation.
GTP binding and GTP hydrolysis regulate the
GTP-dependent kinase activation of LRRK2
Our LRRK2 autophosphorylation and LRRKtide phosphoryl-
ation in vitro kinase assays were conducted in the absence
of additional guanine nucleotides. LRRK2 kinase activity
can be enhanced by the addition of GTP to cell extracts
prior to LRRK2 purification, but GTP does not alter kinase ac-
tivity when added to purified LRRK2 (7,10,11,17), suggesting
that GTP-binding capacity rather than direct binding regulates
the GTP-dependent kinase activation of LRRK2. In order to
explore the effects of functional GTPase domain mutations
on the GTP-dependent kinase activation of LRRK2, we con-
ducted in vitro radioactive kinase assays to measure LRRKtide
phosphorylation using immunopurified, soluble full-length
Figure 3. GTPase activity of LRRK2 GTPase domain mutants. (A) GTP-binding assay by pull-down with GTP-agarose on HEK-293T cell extracts expressing
FLAG-tagged LRRK2 variants. Western blot analysis of GTP-bound fractions (upper panel) and input lysates (lower panel) with anti-FLAG antibody reveals
GTP-bound LRRK2. Molecular weight markers are indicated in kilodaltons. Densitometric analysis of GTP-bound LRRK2 normalized to LRRK2 input levels
expressed as percentage of WT LRRK2. Bars represent mean+SEM (n ¼ 7 experiments) of GTP binding. ∗∗P , 0.01 or ∗∗∗P , 0.001 compared with WT
LRRK2 by one-way ANOVA with the Newman–Keuls post hoc analysis. n.s., not significant. (B) GTP hydrolysis assay monitoring the release of free
g-phosphate from GTP at 30 min intervals over 120 min mediated by immunopurified FLAG-tagged LRRK2. The guanine nucleotide-binding-deficient
T1348N mutant serves as negative control, whereas the GTPase-enhanced R1398L mutant serves as a positive control relative to WT LRRK2. Absorbance
values (indicating Pi concentration) for each LRRK2 variant were normalized to the input level of immunoprecipitated (IP) LRRK2 and expressed as percentage
of WT LRRK2 after 30 min incubation. Data points represent mean+SEM (n ¼ 3 experiments). (C) GTP hydrolysis activity of LRRK2 variants. Assays were
incubated for 120 min. GTPase activity was determined by the normalization of absorbance values to IP LRRK2 levels and expressed as percentage of WT
LRRK2. Bars represent mean+SEM (n ≥ 5 experiments) of GTPase activity. ∗P , 0.05, ∗∗P. 0.01 or ∗∗∗P , 0.001 compared with WT LRRK2 by
one-way ANOVA with the Newman–Keuls post hoc analysis. n.s., not significant.
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LRRK2 derived from cell extracts treated with GTP or GDP or
their non-hydrolyzable analogs bg-methyleneguanosine
5′-triphosphate (GppCp) or guanosine 5′-[b-thio]diphosphate
(GDPbS) at 200 mM, respectively. Treatment with GTP and
GppCp enhances the kinase activity of WT LRRK2, whereas
treatment with GDP but not GDPbS modestly yet significantly
reduces kinase activity compared with untreated LRRK2
(Fig. 5). The guanine nucleotide-binding-deficient T1348N
mutant is kinase-inactive and does not respond to guanine nu-
cleotide treatment, as expected (Fig. 5). GTP enhances the
kinase activity of WT LRRK2 to a significantly greater
extent than non-hydrolyzable GppCp, suggesting that GTP hy-
drolysis may contribute to kinase activity (Fig. 5). Treatment
of the GTPase-enhancing R1398L mutant with GTP or
GppCp enhances kinase activity similar to WT LRRK2 but
with a proportionally greater effect of GTP over GppCp
Figure 4. Kinase activity of LRRK2 GTPase domain mutants. (A) In vitro radioactive kinase assay of LRRK2 autophosphorylation. Autoradiograph (upper
panel) of immunopurified FLAG-tagged LRRK2 variants revealing the incorporation of 33P into LRRK2 by autophosphorylation. Western blot analysis with
anti-FLAG antibody (middle panel) or staining of equivalent SDS–PAGE gels run in parallel with Coomassie colloidal blue (lower panel) indicates the
levels and purity of each immunopurified LRRK2 protein variant. Molecular weight markers are indicated in kilodaltons. (B) Normalization of incorporated
33P to LRRK2 input levels by western blotting. Bars represent the mean+SEM (n ¼ 4–5 experiments) of LRRK2 autophosphorylation levels expressed as
percentage of WT LRRK2. ∗P , 0.05, ∗∗P, 0.01 or ∗∗∗P , 0.001 compared with WT LRRK2, or as indicated, by one-way ANOVA with the Newman–
Keuls post hoc analysis. n.s., not significant. (C) In vitro radioactive kinase assay of LRRK2-mediated phosphorylation of LRRKtide peptide. Incorporation
of 33P into LRRKtide peptide (expressed as radioactive counts per minute) was normalized to the levels of immunoprecipitated LRRK2 for each variant,
and data were expressed as percent of WT LRRK2. Bars represent the mean+SEM (n ¼ 4 experiments) of LRRKtide phosphorylation levels. ∗∗P , 0.01
or ∗∗∗P , 0.001 compared with WT LRRK2, or as indicated, by one-way ANOVA with the Newman–Keuls post hoc analysis. n.s., not significant.
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(Fig. 5), consistent with the enhanced GTP hydrolysis of this
mutant promoting kinase activity in response to GTP. In con-
trast to WT LRRK2, the GTPase-inactive R1398L/T1343V
mutant, which exhibits reduced kinase activity, displays an
equivalent increase in kinase activity with GTP and GppCp
treatment (Fig. 5). The G2019S mutation displays enhanced
kinase activity and responds to guanine nucleotides with a
profile similar to WT LRRK2 (Fig. 5). Interestingly, enhan-
cing (R1398L) or impairing (R1398L/T1343V) GTPase activ-
ity prevents the modest reduction in kinase activity induced by
treatment with GDP compared with WT or G2019S LRRK2
(Fig. 5), potentially suggesting that normal GTP hydrolysis ac-
tivity is required for this effect. Taken together, these data
suggest that normal GTP-binding capacity is required for the
GTP-dependent kinase activation of LRRK2, whereas GTP
hydrolysis is required for the kinase-enhancing effects of
GTP compared with non-hydrolyzable GppCp. The
GTPase-inactive R1398L/T1343V mutant responds equiva-
lently to GTP and GppCp, thus reflecting the baseline contri-
bution of GTP-binding capacity on kinase activity. Our data
suggest that GTP-binding capacity and GTP hydrolysis both
contribute in an additive manner to the GTP-dependent
kinase activation of LRRK2.
GTP binding but not GTP hydrolysis influences LRRK2
dimerization and Hsp90 binding
LRRK2 is capable of forming a dimeric structure mediated
primarily through the COR domain (18–21). Dimerization
appears to be critically required for kinase activity since
monomeric forms of LRRK2 are kinase-inactive, whereas
dimers are kinase-active (19–21). Whether dimerization
equivalently regulates GTPase activity or vice versa is not
yet clear. We considered whether GTPase domain mutations
could influence dimerization and therefore potentially
explain their effects on GTPase activity. We first employed
size-exclusion chromatography (SEC) to examine the effects
of GTPase domain mutations on the formation of
LRRK2-native complexes following their immunopurification
from HEK-293T cells (Fig. 6A and B). WT LRRK2 elutes
over a relatively broad range with the highest signal centered
at 13 ml and the majority of signal estimated to elute
between 440 and 669 kDa compatible with a dimer-sized
LRRK2 complex (Fig. 6A and B). Importantly, the R1398L,
R1398L/T1343V and R1398Q/T1343G mutants do not obvi-
ously influence the hydrodynamic volume of LRRK2 under
native conditions relative to WT protein (Fig. 6A and B).
Next, we examined the capacity of FLAG-tagged LRRK2
mutants to form hetero-dimers with myc-tagged WT LRRK2
by conducting co-immunoprecipitation (IP) experiments
from HEK-293T cells. Myc-tagged WT LRRK2 robustly
immunoprecipitates FLAG-tagged WT LRRK2, suggesting
the formation of LRRK2 dimeric species (Fig. 6C). Mutants
with impaired guanine nucleotide-binding (K1347A, T1348N
and G2019S/T1348N) or kinase activity (D1994A and
G2019S/D1994A) significantly attenuate the formation of
LRRK2 hetero-dimers (Fig. 6C). However, the GTPase-
modifying R1398L and R1398L/T1343V mutants exhibit a
normal capacity to form LRRK2 hetero-dimers (Fig. 6C).
These data suggest that the R1398L and R1398L/T1343V
mutants exhibit a normal capacity to form dimeric structures.
Furthermore, normal GTP-binding capacity and kinase activity
are critically required for LRRK2 dimerization.
The binding of Hsp90 to LRRK2 was recently shown to
reflect LRRK2 protein instability, with increased Hsp90
binding correlating with reduced LRRK2 stability and presum-
ably structure (22). To examine the impact of GTPase muta-
tions on LRRK2 stability, we assessed the interaction of
Figure 5. Role of GTPase activity in guanine nucleotide-dependent kinase activation of LRRK2. In vitro radioactive kinase assay of LRRKtide peptide phos-
phorylation with immunopurified FLAG-tagged LRRK2, following treatment with GTP, GppCp, GDP and GDPbS. The graph indicates the LRRK2-mediated
incorporation of 33P into LRRKtide peptide normalized to the levels of immunoprecipitated LRRK2 and expressed as a percent of WT LRRK2. Guanine nucleo-
tides (200 mM) were added to HEK-293T cell extracts expressing LRRK2 variants, followed by overnight incubation with anti-FLAG-agarose prior to immu-
nopurification and kinase assays. Bars represent the mean+SEM (n ¼ 4–6 experiments) of the level of LRRKtide phosphorylation. ∗P , 0.05, ∗∗P , 0.01 or
∗∗∗P , 0.001 compared with untreated control, or as indicated, for each LRRK2 variant by one-way ANOVA with the Bonferroni post hoc analysis. n.s., not
significant.
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Figure 6. GTP binding but not GTP hydrolysis influences the structural properties of LRRK2. (A) SEC elution profiles of immunopurified FLAG-tagged LRRK2
variants derived from HEK-293T cells (n ¼ 5 experiments) by western dot-blot analysis with anti-FLAG antibody. Indicated are equivalent quantities of 0.5 ml
fractions. The elution of known molecular weight standards is indicated in kilodaltons. (B) Densitometric analysis of individual or combined LRRK2 variant
elution profiles expressed as the relative signal intensity versus fraction number (ml). The table indicates the mean elution fraction for each LRRK2 variant
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LRRK2 functional mutants with endogenous Hsp90 by co-IP
from HEK-293T cells. We find that P-loop mutants
(K1347A, T1348N and G2019S/T1348N) display a markedly
increased interaction with Hsp90 compared with WT
LRRK2 (Fig. 6D), which is consistent with a reduced capacity
to form LRRK2 hetero-dimers (Fig. 6C), reduced GTP binding
(Fig. 3A) and reduced steady-state protein levels (Fig. 2). In
contrast, the GTPase-modifying R1398L and R1398L/
T1343V mutants exhibit normal binding to Hsp90 (Fig. 6D).
Collectively, our data suggest that the GTPase-modifying
mutations, R1398L and R1398L/T1343V, do not influence
LRRK2-native complexes, hetero-dimerization or Hsp90
binding, indicating that these variants do not have adverse
effects on LRRK2 protein stability or structure. Furthermore,
GTPase activity itself does not appear to regulate LRRK2 di-
merization or stability. Importantly, GTP-binding capacity
critically influences the dimerization and structural properties
of LRRK2 protein.
GTP binding and GTP hydrolysis do not regulate the
subcellular localization of LRRK2
LRRK2 normally adopts a diffuse cytoplasmic localization
pattern in mammalian cells (15,16). To examine the effects
of GTPase domain mutations and GTP binding and hydrolysis
on the subcellular localization of LRRK2, we assessed
HEK-293T cells transiently expressing LRRK2 variants by
immunocytochemistry and confocal microscopy. We find
that functional variants (R1398L, R1398L/T1343V, R1398Q/
T1343G, T1348N and D1994A) generally adopt an equivalent
diffuse cytoplasmic distribution pattern similar to WT LRRK2
without evidence of inclusion formation, altered membrane as-
sociation or subcellular compartmentalization (Fig. 7). Our
data suggest that GTP binding and GTP hydrolysis do not
regulate the normal cytoplasmic distribution of LRRK2 in
mammalian cells.
GTPase activity regulates the effects of LRRK2 on neurite
outgrowth
G2019S LRRK2 has been consistently reported to impair the
neurite outgrowth of cultured primary neurons in a kinase-
dependent manner (12,13,23–25). The contribution of
GTPase activity to LRRK2-induced neurite shortening has
not been examined. Therefore, we measured the neurite
length of primary cortical neurons transiently co-expressing
LRRK2 functional mutants and GFP as a marker, using a pre-
viously established assay (12). First, we examined the
Figure 7. GTPase activity does not alter the subcellular localization of LRRK2. Confocal fluorescence microscopy reveals the diffuse cytoplasmic localization of
FLAG-tagged human LRRK2 variants transiently expressed in HEK-293T cells. Staining for LRRK2 (anti-FLAG antibody, green) and nuclei (DAPI, blue) is
indicated. Confocal images are taken from a single z-plane at 0.1 mm thickness. Images are representative of two independent transfection experiments. Scale
bar: 10 mm.
and R2 value for each curve fit. (C) Co-IP analysis of each FLAG-tagged LRRK2 variant with myc-tagged WT LRRK2 from HEK-293T cells. Western blot
analysis of anti-Myc immunoprecipitates (IP; lower panels) or input lysates (upper panel) with anti-FLAG or anti-Myc antibodies is shown. The graph indicates
densitometric analysis of LRRK2 hetero-dimer formation (Myc-LRRK2:FLAG-LRRK2). Data represent the level of IP FLAG-LRRK2 normalized to
FLAG-LRRK2 input levels and further normalized to IP Myc-LRRK2 levels. Data are expressed as a percent of FLAG-LRRK2-WT. Bars represent the
mean+SEM (n ¼ 5 experiments) of hetero-dimer formation. ∗P , 0.05 compared with WT LRRK2 by one-way ANOVA with the Newman-Keuls post hoc
analysis. n.s., not significant. (D) Interaction of endogenous Hsp90 with FLAG-tagged LRRK2 variants in HEK-293T cells by co-IP assay. Western blot analysis
of anti-FLAG IP (lower panels) or input lysates (upper panel) with anti-Hsp90 or anti-FLAG antibodies is shown. The graph indicates densitometric analysis of
LRRK2/Hsp90 interaction levels. Data represent the level of IP Hsp90 normalized to Hsp90 inputs and further normalized to IP FLAG-LRRK2 levels, and finally
expressed as percent of WT LRRK2. Bars represent the mean+SEM (n ¼ 3 experiments) of Hsp90 binding to LRRK2. ∗P , 0.05 or ∗∗∗P , 0.001 compared
with WT LRRK2 by one-way ANOVA with the Newman–Keuls post hoc analysis. n.s., not significant.
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steady-state levels of LRRK2 variants transiently expressed in
primary cortical neurons by western blot analysis. Compared
with WT LRRK2, kinase-inactive mutants (D1994A and
G2019S/D1994A) display markedly reduced protein levels in
neurons, whereas the R1398L, R1398L/T1343V, G2019S,
G2019S/R1398L and G2019S/R1398L/T1343V variants are
detected at normal levels in neurons (Fig. 8A), similar to
HEK-293T cells (Fig. 2). We could further demonstrate that
kinase-inactive (D1994A and D1994N but not K1906M) and
GTP-binding-deficient P-loop (T1348N) mutations reduce
the steady-state levels of LRRK2 in cortical neurons presum-
ably due to reduced protein stability (Supplementary Material,
Fig. S1). Therefore, we restricted our neurite length analysis to
stable variants of LRRK2 with equivalent expression. We find
that the G2019S mutation significantly reduces neurite length,
whereas WT LRRK2 has a smaller effect compared with
control neurons expressing GFP alone (Fig. 8B and C), as pre-
viously described (12,23). The GTPase-inactive R1398L/
T1343V mutant reduces neurite length to a degree similar to
G2019S LRRK2, whereas the GTPase-enhanced R1398L
mutant has an intermediate effect between WT and G2019S
LRRK2 (Fig. 8B and C). Interestingly, the R1398L mutation
is unable to modify the effects of the G2019S mutation on
neurite length, whereas the R1398L/T1343V mutation pro-
vides a modest yet significant rescue of G2019S-induced
neurite shortening (Fig. 8B and C). These neurite length data
correlate with the respective effects of R1398L and R1398L/
T1343V variants on LRRKtide phosphorylation mediated by
G2019S LRRK2 (Fig. 4C), potentially suggesting a kinase-
dependent mechanism. Our data suggest that impairing the
GTPase activity of LRRK2 (i.e. R1398L/T1343V) promotes
neurite shortening but does not further enhance the effects of
the G2019S mutation. Furthermore, enhancing the GTPase ac-
tivity of LRRK2 (i.e. R1398L) is not sufficient to reduce the
effect of the G2019S mutation on neurite length. Collectively,
our data demonstrate that modulating GTPase activity does not
robustly attenuate the inhibitory effect of G2019S LRRK2 on
neurite outgrowth, suggesting that the two enzymatic activities
of LRRK2 (i.e. GTPase and kinase activity) may act independ-
ently of each other to regulate neurite outgrowth.
DISCUSSION
The molecular determinants regulating the GTPase activity of
LRRK2 are poorly characterized. Here, we examine the effects
of modulating GTPase activity on the enzymatic, biochemical
and cellular properties of LRRK2 (Table 1; Supplementary
Material, Table S1). A collection of expression constructs
were generated containing full-length human LRRK2 with
the introduction of various missense mutations located
within key functional residues of the GTPase or kinase
domains. We identified mutations in the GTPase domain that
can either enhance (R1398L) or impair (R1398L/T1343V)
GTPase activity without influencing basal GTP binding. Muta-
tions influencing the GTPase activity of LRRK2 modestly
attenuated kinase activity, whereas in comparison
GTP-binding-deficient mutations dramatically impaired
kinase activity. Furthermore, GTP and its non-hydrolyzable
analog, GppCp, enhanced the kinase activity of WT LRRK2,
whereas the GTPase-inactive variant, R1398L/T1343V,
diminished the effects of GTP but not GppCp on kinase activ-
ity, suggesting that GTP binding and GTP hydrolysis both
contribute to the GTP-dependent kinase activation of
LRRK2. Mutations that alter GTPase activity (R1398L or
R1398L/T1343V) have negligible effects on LRRK2 dimer-
ization and Hsp90 binding, suggesting that these mutations
are likely to exhibit functional rather than destabilizing
effects upon LRRK2. In contrast, GTP-binding-deficient muta-
tions (K1347A or T1348N) critically impair the steady-state
levels, dimerization and structural properties of LRRK2.
Finally, impairing GTPase activity enhances the
LRRK2-dependent inhibition of neurite outgrowth, whereas
enhancing GTPase activity has an intermediate effect. Import-
antly, modulating GTPase activity is not sufficient to robustly
protect against neurite shortening induced by G2019S LRRK2,
suggesting that the kinase and GTPase activities of LRRK2
may act independently to regulate neurite outgrowth. Our
data support a complex regulatory interaction between the
GTPase and kinase domains of LRRK2 and suggest that
GTP-binding capacity and GTP hydrolysis both contribute to
the regulation of kinase activity.
Our prior studies in yeast and neuronal models of
LRRK2-induced toxicity demonstrated an important role for
the GTPase domain in mediating cellular toxicity (13). A
kinase-inactive Roc-COR-kinase domain fragment of
LRRK2 was shown to induce toxicity in yeast and neurons
with mutations that impair GTP binding and hydrolysis (i.e.
K1347A and T1348N) leading to enhanced toxicity and muta-
tions that enhance GTP hydrolysis (R1398L and R1398Q/
T1343G) attenuating the toxic effects of LRRK2 (13). These
previous data suggested that enhancing GTPase activity may
have a protective effect against LRRK2-induced toxicity in
yeast and cultured neurons at least in the context of a truncated
Roc-COR-kinase domain fragment. Motivated by these intri-
guing observations and the paucity of data concerning the
LRRK2 GTPase domain, we sought to explore the functional
effects of similar GTPase domain mutations within the context
of full-length LRRK2 expressed in mammalian cells. Func-
tional missense mutations generally have minimal effects on
the steady-state levels of LRRK2 protein expressed in
Figure 8. GTPase activity regulates the effects of LRRK2 on neurite outgrowth. (A) Western blot analysis with anti-FLAG and anti-b-tubulin antibodies of cell
extracts derived from rat primary cortical neurons at DIV 7 transiently expressing FLAG-tagged human LRRK2 variants. Molecular weight markers are indicated
in kilodaltons. (B) Rat primary cortical neurons co-transfected at DIV 3 with FLAG-tagged human LRRK2 variants (or empty control vector) and GFP plasmids
at a DNA molar ratio of 10:1. Cultures were fixed at DIV 7. Shown are representative fluorescent micrographs revealing the co-labeling of cortical neurons with
GFP, FLAG-LRRK2 and bIII-tubulin for each LRRK2 variant. GFP images were pseudo-colored with ICA to improve the contrast of neuritic processes. Neur-
onal soma are indicated by arrows, and axonal processes are indicated by arrowheads. Scale bars: 400 mm. (C) Analysis of the length of GFP+ neurites from
FLAG+/bIII-tubulin+ cortical neurons. Graph represents axon length for each LRRK2 variant in micrometers (mean+SEM; n ¼ 3–4 cultures). ∗P , 0.05,
∗∗P , 0.01 or ∗∗∗P , 0.001 compared with control, or as indicated, and #P , 0.05 or ###P , 0.001 compared with WT LRRK2, by one-way ANOVA with the
Newman–Keuls post hoc analysis. n.s., not significant.
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HEK-293T cells with the notable exception of
GTP-binding-deficient mutants (i.e. K1347A or T1348N)
which markedly reduce LRRK2 protein levels. Although our
data suggest that GTP-binding-deficient mutants are unstable,
Switch II motif mutations that modulate GTPase activity have
no apparent effects on the steady-state levels of LRRK2.
GTP-binding-deficient mutations also diminished LRRK2
hetero-dimerization in co-IP experiments and promoted the
interaction with Hsp90, suggesting that they lead to protein in-
stability potentially through altering the structural properties
of LRRK2. These data suggest that normal guanine
nucleotide-binding capacity is critically required for maintain-
ing LRRK2 dimerization, structure and ultimately stability.
Our data confirm that P-loop motif mutations impair GTP
binding similar to previous reports and to equivalent mutations
in related small GTPases (7,10,11), whereas Switch II motif
mutants (R1398L, R1398L/T1343V and R1398Q/T1343G)
exhibit normal GTP binding. Notably, kinase activity was
not required for normal GTP binding of LRRK2 despite
recent studies revealing multiple sites of autophosphorylation
within the GTPase domain (26–29), which questions the rele-
vance of LRRK2 autophosphorylation within cells. We further
confirm that P-loop mutations impair GTP hydrolysis, as
expected (7,12,13). Furthermore, kinase activity is not
required for normal GTP hydrolysis, which raises questions
about the exact role of autophosphorylation within the
GTPase domain (26–29). Intriguingly, the R1398L and
R1398L/T1343V variants exhibit robust yet opposite effects
on GTP hydrolysis activity. It is notable that either of the
equivalent mutations in small GTPases such as Ras impairs
GTP hydrolysis and produces a GTP-locked protein that is
constitutively active. Although this appears to be the case
for the GTPase-inactive R1398L/T1343V variant of LRRK2,
the R1398L mutation alone oppositely enhances GTP hydroly-
sis. How these effects are mediated is not clear at present, but
both mutations presumably alter the structural conformation or
flexibility of the GTPase domain but without influencing the
basal GTP-binding affinity, dimerization or native complex
formation of LRRK2. Determination of the crystal structure
of these GTPase-modifying variants within the Roc domain
of LRRK2 may help to shed light on the activation mechanism
regulating the GTPase domain. ROCO proteins have been pos-
tulated to be regulated through a GAD (GTPases activated by
dimerization) mechanism of dimerization in cis whereby the
Roc-COR tandem domain serves as a GAD device, with the
Roc domain mediating GTP binding and hydrolysis and the
COR domain mediating dimerization (30,31). GAD-
containing proteins do not require a GEF or GAP and
instead stimulate GTP hydrolysis via dimerization which is
usually coupled to the interaction with an effector protein
(30). In this context, it is possible that the R1398L/T1343V
and R1398L mutations influence the conformational flexibility
of the Roc-COR tandem domain, thereby altering the GAD
mechanism but without altering dimerization by the COR
domain or GTP binding by the Roc domain. Although an intri-
guing possibility, a GAD mechanism for LRRK2 has not yet
been directly demonstrated and will also require reconciliation
with the observed effects of ArfGAP1, a GTPase-activating
protein, in promoting LRRK2 GTPase activity which would
appear to be inconsistent with a GAD-like mechanism (12,32).
The identification of mutations that functionally and oppos-
itely modify the GTPase activity of LRRK2 offered the possi-
bility to explore how GTPase activity contributes to kinase
activity and cellular phenotypes of LRRK2. Until now, only
the effects of GTP binding upon LRRK2 kinase activity
have been explored with GTP binding promoting kinase activ-
ity through an indirect mechanism that may involve an uniden-
tified guanine nucleotide-binding protein (7,10,11,17). We
demonstrate that enhancing (R1398L) or impairing (R1398L/
T1343V) GTP hydrolysis modestly attenuates LRRK2 kinase
activity, suggesting a role for normal GTPase activity in main-
taining kinase activity. However, in direct comparison, dis-
rupting the GTP-binding capacity (K1347A or T1348N) of
LRRK2 led to a robust and consistent impairment of kinase
activity. We had originally hypothesized that impairing
GTPase activity would prolong the GTP-bound active state
of LRRK2 and thereby enhance kinase activity analogous to
the mechanism of Ras-mediated activation of Raf kinase.
However, this appears not to be the case for the
GTPase-impaired R1398L/T1343V variant, whereas the
recent demonstration that direct GTP binding to LRRK2 in
vitro failed to promote its kinase activity collectively suggests
that the GTPase and kinase domains of LRRK2 are unlikely to
act in a manner analogous to a conventional Ras-Raf mechan-
ism (17). It is possible that GTP hydrolysis per se is required
for kinase activation through a conformational switching
mechanism, with the R1398L and R1398L/T1343V mutations
potentially restricting this conformational flexibility. We re-
cently demonstrated that ArfGAP1 can promote LRRK2
kinase activity, further suggesting a requirement of GTP hy-
drolysis for regulating kinase activity (12). We also examined
the effects of GTPase domain variants on the GTP-dependent
kinase activation of LRRK2, a mechanism that is thought to be
indirect and only occurs in cell extracts prior to LRRK2 puri-
fication rather than in vitro with purified LRRK2 (7,11,17).
Both GTP and its non-hydrolyzable analog, GppCp, enhanced
the kinase activity of WT LRRK2, with a greater effect
observed for GTP over GppCp. Assuming similar binding af-
finities for GTP and GppCp to LRRK2, as recently described
(17), this finding suggests that GTP binding and GTP hydroly-
sis both contribute to the GTP-dependent kinase activation of
LRRK2 since GppCp is non-hydrolyzable and therefore
reflects the contribution of GTP binding only to kinase activa-
tion. The GTPase-inactive R1398L/T1343V variant prevented
the additional kinase-enhancing effect of GTP over GppCp,
further suggesting that GTP hydrolysis contributes to
GTP-dependent kinase activation. That guanine
nucleotide-binding-deficient mutants (K1347A and T1348N)
are kinase-inactive could therefore reflect a combined contri-
bution of impaired GTP binding and GTP hydrolysis. It is
worth noting that the GTPase-inactive R1398L/T1343V
variant consistently exhibits a modest reduction of basal
kinase activity, further supporting a requirement of GTP hy-
drolysis for maintaining normal kinase activity. Collectively,
our data support a contribution of both GTP binding and
GTP hydrolysis to regulating the kinase activity of LRRK2.
We have also explored the effects of modulating GTPase
activity on biochemical and cellular properties of LRRK2.
Since the R1398L/T1343V mutant exhibits impaired GTP hy-
drolysis and kinase activities, we questioned whether these
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mutations could act at a structural level to prevent dimeriza-
tion and therefore explain their functional effects. The
R1398L/T1343V and R1398L mutants could form a normal
range of native LRRK2 complexes compared with WT
LRRK2, consistent with a dimer-sized complex (i.e. 440–
669 kDa) as well as recently described LRRK2 complexes
associated with Hsp90 (.669 kDa) (19–22). Therefore,
altered GTPase activity most likely does not result from abnor-
mal LRRK2 complex formation including dimerization. The
formation of apparent LRRK2 dimers observed by SEC has
recently been questioned (33). However, we were able to dem-
onstrate that LRRK2 can form hetero-oligomers by co-IP
assays with alternatively tagged proteins that most likely
reflect LRRK2 dimers based upon the native LRRK2 com-
plexes revealed by SEC. Although this represents an indirect
assay of dimerization, the R1398L/T1343V and R1398L
mutants exhibited a normal capacity to form hetero-dimers
with WT LRRK2 compared with guanine nucleotide-
binding-deficient (K1347A or T1348N) and kinase-inactive
(D1994A) mutations which markedly impair dimer formation.
Collectively, our data suggest that the GTPase-modifying
mutants do not adversely influence LRRK2 dimerization and
complex formation, suggesting that (i) the effects of these
functional mutations on GTP hydrolysis do not result from
altered dimerization and that (ii) GTP hydrolysis itself does
not obviously regulate LRRK2 dimerization or complex for-
mation. The R1398L/T1343V and R1398L variants are there-
fore likely to alter LRRK2 conformation or structural
flexibility locally within the GTPase domain in a subtle
manner without compromising LRRK2 dimerization or stabil-
ity. Hsp90 binding to LRRK2 was recently suggested to cor-
relate with a loss of LRRK2 structure, as shown for the
kinase-impaired G2385R mutation associated with an
increased risk for PD (22). Importantly, the R1398L/T1343V
and R1398L variants exhibited normal Hsp90 binding, imply-
ing that these LRRK2 variants adopt a normal structure, con-
sistent also with a normal capacity to form LRRK2 complexes
and hetero-dimers. Of interest, the guanine nucleotide-
binding-deficient mutants, K1347A and T1348N, display
increased binding to Hsp90, consistent with their reduced
stability and impaired hetero-dimer formation potentially
resulting from a loss of LRRK2 structure. The kinase-inactive
mutation, D1994A, also exhibited impaired hetero-
dimerization consistent with previous reports suggesting a re-
quirement of kinase activity for LRRK2 dimerization (21).
Caution is therefore warranted for the interpretation of cellular
phenotypes modulated by guanine nucleotide-binding-
deficient mutations (i.e. K1347A or T1348N) since they sim-
ultaneously impair LRRK2 GTP binding, dimerization and
structure, which could all result in attenuated kinase activity.
How P-loop mutants lead to unstable forms of LRRK2 is
not clear but could potentially result from a loss of structure
and dimerization. Our data support the development of
strategies for interfering with guanine nucleotide binding via
the P-loop motif as an attractive therapeutic mechanism for
attenuating the enhanced LRRK2 kinase activity and neuronal
toxicity due to the pathogenic G2019S mutation.
LRRK2 can regulate neurite complexity with certain
PD-associated mutations leading to reduced neurite length
and branching, whereas LRRK2 silencing or deletion has
opposing effects (23,24,34). The effects of the G2019S muta-
tion on neurite length are reported to be kinase-dependent
(23,25). However, some caution is warranted with such inter-
pretations since we demonstrate that certain kinase-inactive
mutations [i.e. D1994A and D1994N, or D1994S (35)]
create unstable forms of LRRK2 when expressed in primary
neurons compared with mammalian cell lines. We therefore
recommend the use of the kinase-inactive K1906M mutation
for neuronal culture experiments, which has minimal effects
on LRRK2 stability. The contribution of the GTPase domain
to LRRK2-induced neurite shortening has not yet been
explored. We initially found that the T1348N mutation
impairs the stability of LRRK2 protein in cortical neurons,
similar to HEK-293T cells, thereby rendering it refractory to
further analysis in our neurite length assay. We find that the
R1398L/T1343V mutant impaired neurite outgrowth to an
extent similar to G2019S LRRK2. The G2019S variant robust-
ly enhances kinase activity but does not influence GTP binding
or hydrolysis in the present study, whereas the R1398L/
T1343V variant exhibits impaired GTPase activity and
reduced kinase activity. Therefore, it is likely that locking
LRRK2 in a GTP-bound conformation rather than lowering
kinase activity is responsible for the effects of the R1398L/
T1343V variant on neurite length. The GTPase-enhanced
R1398L mutant, which has inconsistent effects on kinase ac-
tivity, also induced neurite shortening but to a smaller
extent, suggesting that GTPase activity may contribute to the
inhibitory effects of LRRK2 on neurite outgrowth in a
manner potentially independent of kinase activity. Finally,
modulating GTPase activity did not robustly rescue or exacer-
bate G2019S LRRK2-induced neurite shortening, suggesting
that the G2019S mutation may act through a GTPase
activity-independent mechanism (i.e. kinase-dependent) or
has a dominant effect over GTPase activity. These observa-
tions are consistent with the inability of R1398L or R1398L/
T1343V mutations to influence the elevated kinase activity
of G2019S LRRK2, whereas these GTPase domain mutations
alone modestly attenuated kinase activity (Fig. 4). Taken
together, these data suggest that GTPase activity is not
capable of robustly modifying the inhibitory effects of the
G2019S mutation on neurite outgrowth. If one assumes that
neurite-shortening phenotypes reflect neuronal toxicity to
some extent, then our data suggest that modulating GTP
hydrolysis may not provide a promising strategy for inhibiting
the neurotoxic actions of the pathogenic G2019S mutation.
Our future studies using an adenoviral-mediated rat model of
G2019S LRRK2-induced neurodegeneration will hope to
clarify the potential neuroprotective effects of genetically
modulating GTP-binding and GTP hydrolysis activity (36).
It will be important in future studies to explore the contribu-
tion of GTPase activity to the neurotoxic actions of other
PD-associated LRRK2 mutations (i.e. R1441C, R1441G or
Y1699C) located within the Roc-COR domains that exhibit
normal kinase activity but a modest impairment of GTP hy-
drolysis (4,13,14,37).
In summary, we have conducted a comprehensive and com-
parative analysis of the effects of functional GTPase domain
mutations on the enzymatic activity, biochemical and cellular
phenotypes of LRRK2 (Table 1; Supplementary Material,
Table S1). Importantly, our study demonstrates a critical
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requirement of guanine nucleotide binding and, to a lesser
extent, GTP hydrolysis for normal kinase activity, and sug-
gests that GTP binding and GTP hydrolysis can both contrib-
ute to the GTP-dependent kinase activation of LRRK2.
Guanine nucleotide binding further plays a role in maintaining
the normal dimerization, structure and stability of LRRK2
protein. Furthermore, GTP hydrolysis activity regulates the
LRRK2-dependent inhibition of neurite outgrowth independ-
ent of kinase activity, although modulating GTP hydrolysis ac-
tivity is not sufficient to robustly rescue the effects of
pathogenic G2019S LRRK2 on neurite length, consistent
with the inability of GTP hydrolysis activity to alter the
kinase activity of G2019S LRRK2. Our data further dissects
and elucidates the contribution of the GTPase domain to the
enzymatic activity, biochemical and cellular properties of
LRRK2. Our study suggests that strategies aimed at interfering
with guanine nucleotide binding rather than modulating GTP
hydrolysis may provide an attractive therapeutic mechanism
for inhibiting the elevated LRRK2 kinase activity and neuro-
degeneration due to the pathogenic G2019S mutation.
MATERIALS AND METHODS
Animals
All animal experiments were approved by the SCAV (Service
de la consommation et des affaires ve´te´rinaires) in the Canton
de Vaud (Animal authorization No. 2293), and conducted in
strict accordance with the European Union directive (2010/
63/EU) for the care and use of laboratory animals. Animals
were maintained in a pathogen-free barrier facility and
exposed to a 12 h light/dark cycle with food and water pro-
vided ad libitum. Pregnant female Sprague–Dawley rats
were obtained from Charles River Laboratories (L’Arbresle
Cedex, France), and resulting P0–P1 rats were used for the
preparation of post-natal primary cortical cultures.
Expression plasmids, proteins and antibodies
Mammalian expression plasmids containing 3× FLAG-tagged
full-length human LRRK2 (WT and G2019S) were kindly pro-
vided by Dr Christopher Ross (Johns Hopkins University, Bal-
timore, MD, USA) (38). Functional missense mutations were
introduced in FLAG-tagged LRRK2 by site-directed mutagen-
esis, using the QuikChange II XL kit (Agilent Technologies,
La Jolla, CA, USA) and verified by DNA sequencing. Myc-
tagged human WT LRRK2 plasmid was kindly provided by
Dr Ted M. Dawson (Johns Hopkins University) (15). As
control plasmids, pEGFP-N1 was obtained from Clontech
(Mountain View, CA, USA) and pcDNA3.1-myc-his was
obtained from Invitrogen (Basel, Switzerland). LRRKtide
peptide (RLGRDKYKTLRQIRQ; 97.6% pure by HPLC ana-
lysis) was purchased from SignalChem (Richmond, Canada).
GTP, GppCp, GDP and GDPbS at .95% purity by HPLC
were purchased from Sigma-Aldrich (Buchs, Switzerland).
3× FLAG peptide was purchased from Sigma-Aldrich.
The following antibodies were employed: mouse monoclonal
anti-FLAG-(M2), anti-FLAG-(M2)-peroxidase and anti-b-
tubulin (clone TUB 2.1), and rabbit polyclonal anti-bIII-
tubulin (Sigma-Aldrich); anti-c-myc (clone 9E10) and
anti-c-myc-peroxidase (Roche Applied Science, Basel, Switz-
erland); mouse monoclonal anti-Hsp90 (BD Biosciences,
Allschwil, Switzerland); peroxidase-coupled anti-mouse IgG
(Jackson ImmunoResearch, Inc., West Grove, PA, USA); anti-
mouse IgG coupled to AlexaFluor-488 or AlexaFluor-546 and
anti-rabbit IgG coupled to AlexaFuor-633 (Invitrogen).
Cell culture and transient transfection
HEK-293T cells were maintained in Dulbecco’s modified
Eagle’s media supplemented with 10% fetal bovine serum
and 1× penicillin/streptomycin at 378C and in a 5% CO2 at-
mosphere. Cells were transfected with plasmid DNAs, using
X-tremeGENE HP DNA Transfection Reagent (Roche
Applied Science) according to the manufacturer’s recommen-
dations. Cells were harvested at 48–72 h post-transfection for
biochemical assays.
Co-IP assays and western blotting
For co-IP assays, HEK-293T cells were transiently transfected
with each plasmid in 10 cm dishes and harvested after 48 h in
1 ml of IP buffer [10 mM Tris–HCl pH 7.5, 150 mM NaCl, 1%
NP-40, 1× phosphatase inhibitor cocktail 2 and 3
(Sigma-Aldrich), 1× Complete Mini Protease Inhibitor Cock-
tail (Roche Applied Sciences)]. Cell lysates were rotated at
48C for 1 h and soluble fractions were obtained by centrifuga-
tion at 17 500g for 15 min at 48C. Soluble fractions were com-
bined with 50 ml of Protein G-Dynabeads (Invitrogen)
pre-incubated with mouse anti-FLAG (5 mg; Sigma-Aldrich)
or anti-myc (5 mg; Roche Applied Sciences) antibodies and
incubated overnight at 48C. Dynabead complexes were
washed three times with IP buffer supplemented with
450 mM NaCl and twice with IP buffer. Immunoprecipitates
were eluted by heating at 708C for 10 min in Laemmli
sample buffer (Bio-Rad AG, Reinach, Switzerland) containing
5% 2-mercaptoethanol. IPs and inputs (1% total lysate) were
resolved by SDS–PAGE, transferred to Protran nitrocellulose
(0.2 mM; Perkin Elmer, Schwerzenbach, Switzerland) and sub-
jected to western blot analysis with appropriate primary and
secondary antibodies. Proteins were visualized by enhanced
chemiluminescence (ECL; GE Healthcare, Glattbrugg, Switz-
erland) on a FujiFilm LAS-4000 Luminescent Image Analysis
system. The LabImage 1D software (Kapelan Bio-Imaging
Solutions, Leipzig, Germany) was used for the quantitation
of protein levels by densitometry.
To assess the steady-state protein levels of LRRK2 mutants,
transfected HEK-293T cells were lysed in buffer A [1× PBS
pH 7.5, 1% Triton X-100, 1× phosphatase inhibitor cocktail 2
and 3 (Sigma-Aldrich), 1× Complete Mini Protease Inhibitor
Cocktail (Roche Applied Science)] by rotating for 1 h at 48C.
Clarified lysates were obtained by centrifugation at 17 500g
for 15 min at 48C. The detergent-soluble supernatant fraction
was quantified by BCA assay (Pierce Biotechnology, Rock-
ford, IL, USA), and proteins (30 mg) were resolved by
SDS–PAGE and subjected to western blot analysis with
appropriate primary and secondary antibodies.
Human Molecular Genetics, 2013, Vol. 22, No. 6 1153
Immunocytochemistry and confocal microscopy
HEK-293T cells were seeded on glass cover slips in 35 mm
dishes at a density of 80 000 cells/dish and transfected with
FLAG-tagged LRRK2 variants. At 48 h post-transfection,
cells were fixed in 4% paraformaldehyde (PFA) and processed
for immunocytochemistry with mouse anti-FLAG antibody
and anti-mouse IgG-AlexaFluor-488 antibody and stained
with DAPI. Fluorescent images were acquired using a Zeiss
LSM 700 inverted confocal microscope (Carl Zeiss AG, Feld-
bach, Switzerland) with a Plan-Apochromat 63×/1.40 oil ob-
jective in x, y and z planes. Images were subjected to
deconvolution, using the HuygensPro software (Scientific
Volume Imaging, Hilversum, The Netherlands). Representa-
tive images are taken from a single z-plane at a thickness of
0.1 mm.
Size-exclusion chromatography
HEK-293T cells were lysed in buffer B [20 mM Tris–HCl, pH
7.5, 150 mM NaCl, 1 mM EDTA, 0.5% Tween 20, 1× phosphat-
ase inhibitor cocktail 2 and 3 (Sigma-Aldrich), 1× Complete
Mini Protease Inhibitor Cocktail (Roche Applied Science)].
Cleared lysates (1 ml) were incubated with
anti-FLAG-M2-agarose beads by rotating overnight at 48C.
Resin complexes were washed with different buffers (2× with
20 mM Tris–HCl, 500 mM NaCl, 0.5% Tween 20;
2× with 20 mM Tris–HCl, 300 mM NaCl, 0.5% Tween 20; 2×
with 20 mM Tris–HCl, 150 mM NaCl, 0.5% Tween 20; 2×
with 20 mM Tris–HCl, 150 mM NaCl, 0.1% Tween; and
2× with 20 mM Tris–HCl, 150 mM NaCl, 0.02% Tween 20),
and LRRK2 proteins were eluted in elution buffer (20 mM
Tris–HCl, pH 7.5, 150 mM NaCl, 0.02% Tween 20 and
150 mg/ml of 3× FLAG peptide) for 30 min at 48C with
shaking. Eluted proteins were resolved by SDS–PAGE and
stained with Coomassie G-250 to verify protein purity, and
LRRK2 content was calculated by densitometry, using a standard
curve with bovine serum albumin (BSA). Purified proteins con-
taining equal amounts of each FLAG-LRRK2 variant were
injected into an AKTA Purifier FPLC system (GE Healthcare,
Italy) and separated using a Superose 6 10/300 column (GE
Healthcare, Italy), after equilibration with buffer C (20 mM
Tris–HCl, pH 7.5, 150 mM NaCl and 0.07% Tween 20). Pump
flow rate was fixed at 0.5 ml/min. Elution volumes of standards
were 7.5 ml for Blue Dextran (V0), 12.37 ml for thyroglobin
(669 kDa), 14.21 ml for ferritin (440 kDa) and 15.71 ml for cata-
lase (232 kDa). Each separated fraction obtained by FPLC ana-
lysis (1 ml) was spotted on nitrocellulose membranes, incubated
with anti-FLAG-peroxidase (Sigma-Aldrich) and subjected to de-
tection with ECL.
GTP binding assay
HEK-293T cells expressing FLAG-tagged LRRK2 variants
were lysed in buffer A [1× PBS, pH 7.5, 1% Triton X-100,
1× phosphatase inhibitor cocktail 2 and 3 (Sigma-Aldrich),
1× Complete Mini Protease Inhibitor Cocktail (Roche
Applied Science)] by rotating for 1 h at 48C. Soluble fractions
were incubated with 25 ml of guanosine 5′-triphosphate–
agarose (Sigma-Aldrich) by rotating for 2 h at 48C. Agarose
beads were washed three times with buffer A and once with
1× PBS. GTP-bound fractions were eluted in Laemmli
buffer containing 5% 2-mercaptoethanol and heating at 708C
for 10 min. GTP-bound fractions and inputs lysates (1%
total lysate) were resolved by SDS–PAGE and subjected to
western blot analysis with anti-FLAG-peroxidase antibody.
GTP hydrolysis assay
GTP hydrolysis assay was performed as previously described
(12,13) by measuring the release of free g-phosphate (Pi) from
GTP, using the high-sensitivity colorimetric GTPase assay kit
(Innova Biosciences, Cambridge, UK). To establish time
curves for LRRK2 GTPase activity, HEK-293T cells transient-
ly expressing FLAG-tagged LRRK2 variants (WT, T1348N
and R1398L) were lysed in phosphate-free lysis buffer
[10 mM Tris–HCl, pH 7.5, 150 mM NaCl, 1% NP-40, 1×
phosphatase inhibitor cocktail 2 and 3 (Sigma-Aldrich), 1×
Complete Mini Protease Inhibitor Cocktail (Roche Applied
Science)]. Following centrifugation at 17 500g for 15 min,
supernatant fractions were subjected to IP with 2.5 mg of anti-
FLAG antibody pre-incubated with 25 ml of Protein G-
Dynabeads (Invitrogen) by rotating at 48C overnight. As
control for protein contamination, mock-transfected
HEK-293T cell lysates were subjected to IP with anti-FLAG
antibody. Dynabeads were washed five times with lysis
buffer and once with 0.5 M Tris–HCl, pH 7.5, then resus-
pended in 100 ml of 0.5 M Tris–HCl, pH 7.5, and finally sub-
jected to GTP hydrolysis assays in 96-well plates in assay
buffer containing 0.25 mM GTP. Reactions were incubated
for 30, 60, 90 and 120 min at room temperature according to
the manufacturer’s recommendations. Assay samples were
measured for absorbance at 635 nm, and Pi concentration
was determined from standard curves. The control absorbance
value for the mock IP FLAG sample was deducted from the
absorbance values obtained for each LRRK2 sample. FLAG
IP samples (5 ml of total) were subjected to western blotting
with anti-FLAG antibody to confirm LRRK2 immunopurifica-
tion. The levels of each IP LRRK2 variant was quantified by
densitometry and used to normalize LRRK2-mediated Pi
release in each experiment. Data were expressed as a
percent of Pi release due to WT LRRK2 after 30 min. Subse-
quent LRRK2 GTPase assays were conducted as described
earlier with incubation for 120 min at room temperature,
with GTPase activity (Pi release) expressed as a percent of
WT LRRK2.
In vitro kinase assays
Autophosphorylation assay
For LRRK2 autophosphorylation, transfected HEK-293T cells
were lysed, subjected to IP with anti-FLAG-agarose, and
LRRK2 proteins were eluted with 3× FLAG peptide as
described earlier. Eluted proteins were resolved by SDS–
PAGE and stained with Coomassie G-250 (Bio-Rad) to
verify protein purity, and LRRK2 content was calculated by
densitometry, using a standard curve with BSA. Autopho-
sphorylation reactions were performed in kinase buffer
(25 mM Tris–HCl, pH 7.5, 5 mM b-glycerophosphate, 2 mM
dithiothreitol, 0.1 mM Na3VO4, 10 mM MgCl2) in the presence
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of [33P]-g-ATP (2 mCi/reaction; Perkin Elmer, MA, USA) and
5 mM cold ATP (Sigma-Aldrich) at 308C for 1 h in a final
volume of 25 ml. Reactions were terminated with 4×
Laemmli buffer and by boiling at 958C for 10 min. Autopho-
sphorylation reaction samples were resolved on 4–16% SDS–
PAGE pre-cast gels (Invitrogen) and transferred to PVDF
membranes. Incorporated radioactivity was detected by auto-
radiography and the same membranes were probed with anti-
FLAG antibody and western blot detection as a protein-
loading control. Relative LRRK2 autophosphorylation was
determined by densitometric analysis of 33P autoradiograph
signals for LRRK2 normalized to LRRK2 protein levels.
LRRKtide phosphorylation assay
To measure LRRKtide phosphorylation, HEK-293T cells were
lysed, subjected to IP with anti-FLAG-agarose, and LRRK2
proteins were eluted with 3× FLAG peptide and quantified
as described earlier. For treatment with GTP, GppCp, GDP
and GDPbS, guanine nucleotides (200 mM) were added to
cell lysates immediately prior to incubation with anti-
FLAG-agarose, followed by rotation overnight at 48C. For
LRRKtide phosphorylation assay, LRRKtide peptide
(400 mM) was added to standard kinase reactions, as described
earlier. Reaction samples were terminated by the addition
of 8 ml of 0.5 M EDTA and samples were applied to P81
phosphocellulose paper (Whatman, Opfikon, Switzerland).
P81 squares were dried, washed three times with 75 mM
phosphoric acid (Sigma-Aldrich) and incorporated 33P into
LRRKtide peptide was detected by scintillation counting.
LRRKtide phosphorylation levels were normalized to the
levels of LRRK2 protein determined by western blotting and
densitometry.
Primary neuronal cultures and neurite length assays
Primary neuronal cultures
Primary cortical neurons were prepared from Sprague–
Dawley P0–P1 rats by stereoscopically isolating the cerebral
cortices and dissociation by digestion in media containing
papain (20 U/ml, Sigma-Aldrich) and mechanical trituration.
Cells were plated in 35 mm dishes on glass cover slips
coated with poly-D-lysine (20 ng/ml; BD Biosciences) and
mouse laminin (33 mg/ml; Invitrogen) and cultured in Neuro-
basal media containing B27 supplement (2% w/v),
L-glutamine (500 mM) and penicillin/streptomycin (100 U/ml)
(Invitrogen).
Neurite length assay
Primary cortical neurons were co-transfected at DIV 3 with
FLAG-tagged LRRK2 variants and GFP plasmids at a 10:1
DNA molar ratio (4 mg of total DNA per 35 mm dish),
using Lipofectamine 2000 reagent (Invitrogen). At DIV 7, cul-
tures were fixed with 4% PFA and processed for immunocyto-
chemistry, using mouse anti-FLAG antibody (Sigma-Aldrich),
rabbit anti-bIII-tubulin (Sigma-Aldrich), anti-mouse
IgG-AlexaFluor-546 and anti-rabbit IgG-AlexaFluor-633 anti-
bodies (Invitrogen). Fluorescent images were acquired using
an EVOS inverted fluorescence digital microscope (Advanced
Microscopy Group, Bothell, WA, USA) with a ×10 objective.
GFP images were pseudo-colored with ICA1 using the NIH
ImageJ software to improve the contrast of neuritic processes,
and used for neurite length measurements. The length of
GFP-positive axonal processes from FLAG-positive cortical
neurons (bIII-tubulin-positive) was measured using the line
tool function of the ImageJ software by an investigator
blinded to each condition. Only neurons that had extended
neurites were measured, whereas neurons without processes
were excluded from the analysis. For each experiment,
axonal processes from 30 GFP-positive neurons randomly
sampled across five cover slips from at least three independent
experiments were measured.
Statistical analysis
Data were analyzed by one-way ANOVA with the Newman–
Keuls multiple comparison test or the Bonferroni post hoc test.
P , 0.05 was considered significant. Fitting curves of SEC
fractions were obtained by Gaussian regression fit analysis.
SUPPLEMENTARY MATERIAL
Supplementary Material is available at HMG online.
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